[{"id":"b4d402cb-9b95-4ade-8b2a-ba008e6e8258","acronym":"","url":"https://clinicaltrials.gov/study/NCT04234048","created_at":"2021-01-18T20:35:42.430Z","updated_at":"2024-07-02T16:34:26.824Z","phase":"Phase 1","brief_title":"Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04234048","lead_sponsor":"SciTech Development, LLC","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fenretinide nanoparticle (ST-001 nanoFenretinide)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-06-12"},{"id":"e5ec4f89-3dbd-44a0-840b-43fddf551b2c","acronym":"OPTICOV","url":"https://clinicaltrials.gov/study/NCT05587894","created_at":"2022-10-20T14:11:40.949Z","updated_at":"2024-07-02T16:35:12.457Z","phase":"Phase 2","brief_title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","source_id_and_acronym":"NCT05587894 - OPTICOV","lead_sponsor":"ANRS, Emerging Infectious Diseases","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 256","initiation":"Initiation: 04/27/2023","start_date":" 04/27/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-03-28"},{"id":"7a766258-ef73-4c74-938d-a1a53533819e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04365933","created_at":"2021-01-18T21:05:55.917Z","updated_at":"2024-07-02T16:36:04.856Z","phase":"Phase 2a","brief_title":"A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir","source_id_and_acronym":"NCT04365933","lead_sponsor":"Enyo Pharma","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/25/2020","start_date":" 05/25/2020","primary_txt":" Primary completion: 06/16/2021","primary_completion_date":" 06/16/2021","study_txt":" Completion: 11/29/2021","study_completion_date":" 11/29/2021","last_update_posted":"2022-08-25"},{"id":"0dd3a28d-1be7-40ff-a066-40868ec0b07e","acronym":"KG 4/2015","url":"https://clinicaltrials.gov/study/NCT02854072","created_at":"2021-01-18T14:00:33.938Z","updated_at":"2024-07-02T16:37:27.514Z","phase":"Phase 3","brief_title":"A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients","source_id_and_acronym":"NCT02854072 - KG 4/2015","lead_sponsor":"Samsung Pharmaceutical Co., Ltd.","biomarkers":" CCL11 • CA 19-9","pipe":"","alterations":" ","tags":["CCL11 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • LucaVax (tertomotide)"],"overall_status":"Unknown status","enrollment":" Enrollment 148","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2016-11-22"}]